Novartis dumps Rett gene therapy caught up in Zolgensma scandal in cull of pipeline prospects

Novartis has scrapped work on its Rett syndrome gene therapy AVXS-201 after finding the data don’t support further development. The action follows Novartis’ decision to gather extra data on the candidate in response to data manipulation during development of Zolgensma.